Financial news, mergers and acquisitions, partnerships, and alliances.
Puma provided an update on its plan for Nerlynx and Natera discussed the cancer trials its Signatera test is being used in.
Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.